Kobrin S M, Goldstein S J, Shangraw R F, Raja R M
Albert Einstein Medical Center, Kraftsow Division of Nephrology, Philadelphia, PA 19141.
Am J Kidney Dis. 1989 Dec;14(6):461-5. doi: 10.1016/s0272-6386(89)80145-3.
Orally administered calcium carbonate tablets are commonly prescribed as a calcium supplement and for their phosphate-binding effects in renal failure patients. Two cases are reported in which a commercially available brand of calcium carbonate tablets appeared to be ineffective. Formal investigation of the bioavailability of this product revealed it to have impaired disintegration and dissolution and a lack of clinical efficacy. Recommendations that will enable physicians to avoid prescribing and pharmacists to avoid dispensing ineffective calcium carbonate tablets are proposed.
口服碳酸钙片通常被用作钙补充剂，并用于肾衰竭患者的磷结合作用。本文报告了两例市售品牌碳酸钙片似乎无效的病例。对该产品生物利用度的正式调查显示，其崩解和溶解受损且缺乏临床疗效。本文提出了一些建议，以使医生避免开具以及药剂师避免配发无效的碳酸钙片。
